Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.

MLA

Cárdenas, Vicky, et al. “Safety and Immunogenicity of Ad26.COV2.S in Adults: A Randomised, Double-Blind, Placebo-Controlled Phase 2a Dose-Finding Study.” Vaccine, vol. 42, no. 16, June 2024, pp. 3536–46. EBSCOhost, https://doi.org/10.1016/j.vaccine.2024.04.059.

APA

Cárdenas, V., Le Gars, M., Truyers, C., Ruiz-Guiñazú, J., Struyf, F., Colfer, A., Bonten, M., Borobia, A., Reisinger, E. C., Kamerling, I. M. C., Douoguih, M., & Sadoff, J. (2024). Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study. Vaccine, 42(16), 3536–3546. https://doi.org/10.1016/j.vaccine.2024.04.059

Chicago

Cárdenas, Vicky, Mathieu Le Gars, Carla Truyers, Javier Ruiz-Guiñazú, Frank Struyf, Alicia Colfer, Marc Bonten, et al. 2024. “Safety and Immunogenicity of Ad26.COV2.S in Adults: A Randomised, Double-Blind, Placebo-Controlled Phase 2a Dose-Finding Study.” Vaccine 42 (16): 3536–46. doi:10.1016/j.vaccine.2024.04.059.